Kedrion SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kedrion SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5144
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kedrion SpA (Kedrion) collects and fractionates blood plasma to develop, produce and distribute plasma-derived therapies. The company’s products are used for the treatment of rare and serious disorders such as hemophilia, immune deficiency and neurological disorders. It also offers products for the treatment of orphan diseases. Kedrion also offers contract manufacturing services, technology transfer services and biological safety center services. The company works in partnership with Italian National Health Service to achieve self-sufficiency in plasma-derived therapies. It has manufacturing plants in Italy, Hungary and the US. The company has operational presence in Asia, Europe, North America and South America. Kedrion is headquartered in Barga, Lucca, Italy.

Kedrion SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kedrion SpA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 12
Partnerships 13
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
Licensing Agreements 15
United Biotech Enters into Licensing Agreement with Kedrion 15
Debt Offering 16
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 16
Kedrion Raises USD514 Million in Private Placement of Bonds 17
Acquisition 18
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 18
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 19
Kedrion SpA – Key Competitors 20
Kedrion SpA – Key Employees 21
Kedrion SpA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Kedrion SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 12
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
United Biotech Enters into Licensing Agreement with Kedrion 15
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 16
Kedrion Raises USD514 Million in Private Placement of Bonds 17
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 18
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 19
Kedrion SpA, Key Competitors 20
Kedrion SpA, Key Employees 21
Kedrion SpA, Subsidiaries 22

List of Figures
Kedrion SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Kedrion SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vallourec Sa
    Vallourec Sa - Strategy, SWOT and Corporate Finance Report Summary Vallourec Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Biotec Pharmacon ASA (BIOTEC):医療機器:M&Aディール及び事業提携情報
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Insulet Corp (PODD):製薬・医療:M&Aディール及び事業提携情報
    Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. Its OmniPod insulin management system is a continuous insulin delivery system for insulin dependent diabetic s. Omnipod system consists of a dispos …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • ICF International, Inc.:企業の戦略・SWOT・財務分析
    ICF International, Inc. - Strategy, SWOT and Corporate Finance Report Summary ICF International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • University of Cape Town-製薬・医療分野:企業M&A・提携分析
    Summary University of Cape Town (UCT) is a public research university that offers educational services. The university offers services for faculty of commerce, faculty of engineering and the built environment, faculty of health sciences, faculty of humanities, faculty of law and faculty of science. …
  • Hitachi Zosen Corporation:戦略・SWOT・企業財務分析
    Hitachi Zosen Corporation - Strategy, SWOT and Corporate Finance Report Summary Hitachi Zosen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aldi Einkauf GmbH & Co oHG:企業の戦略・SWOT・財務分析
    Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report Summary Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Orthofix International N.V. (OFIX):医療機器:M&Aディール及び事業提携情報
    Summary Orthofix International NV (Orthofix) is a medical device company that designs, develops, manufactures and distributes medical devices related to spine and orthopedic. Its solutions include spinal implants; human cellular and tissue based products; non-invasive regenerative stimulation produc …
  • PIQUR Therapeutics AG-製薬・医療分野:企業M&A・提携分析
    Summary PIQUR Therapeutics AG (PIQUR) is a clinical-stage pharmaceutical company that discovers and develops anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipe …
  • Seattle Genetics Inc (SGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The company's lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate indicated for the treatment of relapsed …
  • Vaccibody AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vaccibody AS (Vaccibody) is a vaccine company that provides discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines. The company develops VB10.16, a DNA based immunotherapy targeting malignancies caused by human papilloma virus. It conducts exploratory safet …
  • CA, Inc.:企業のM&A・事業提携・投資動向
    CA, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CA, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • The Portage la Prairie Mutual Insurance Company:企業の戦略的SWOT分析
    The Portage la Prairie Mutual Insurance Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Cordis Corp:医療機器:M&Aディール及び事業提携情報
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …
  • Opus International Consultants Ltd:企業の戦略・SWOT・財務情報
    Opus International Consultants Ltd - Strategy, SWOT and Corporate Finance Report Summary Opus International Consultants Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • University of Wollongong:企業の戦略的SWOT分析
    University of Wollongong - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Aker ASA (AKER):石油・ガス:M&Aディール及び事業提携情報
    Summary Aker ASA (Aker) is an industrial investment company that operates through Industrial Holdings and Financial Investments. It invests mainly in energy, environment, fisheries and marine biotech, and finance. Its Industrial Holdings include Aker Solutions ASA, Aker BP, Akastor ASA, Ocean Yield …
  • Boursorama Sa
    Boursorama Sa - Strategy, SWOT and Corporate Finance Report Summary Boursorama Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Hargreaves Services Plc:企業の戦略・SWOT・財務情報
    Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆